Published studies showed 94% efficacy for antidepressants, but FDA files revealed half of trials were negative. Companies buried unfavorable results through selective publication.
“All clinical trial data has been transparently reported to regulators”
From “crazy” to confirmed
The Claim Is Made
This is the moment they called it crazy.
When your doctor prescribes an antidepressant, they're relying on what they believe is solid evidence. Published clinical trials consistently showed these medications worked for roughly 94% of patients. The data seemed overwhelming. What doctors didn't know was that they were seeing only half the story.
For decades, the pharmaceutical industry conducted hundreds of clinical trials testing antidepressants. Many of these trials produced disappointing results. The drugs didn't work better than placebo, or they caused unacceptable side effects. Yet these negative findings rarely appeared in medical journals. Instead, companies selectively published the positive trials while the unfavorable ones languished in filing cabinets and company databases.
The FDA possessed the complete picture. Regulators at the agency reviewed all trial data—both published and unpublished—before approving medications. But this crucial information stayed locked away in government files. Psychiatrists writing treatment guidelines, medical schools training new doctors, and patients making decisions about their care had no access to it. They operated on incomplete information that systematically overstated how well these drugs worked.
Industry executives weren't secretive about this practice. It was standard business procedure. Publishing negative results would hurt sales. Companies that conducted unfavorable trials simply chose not to submit them for journal publication, or they framed disappointing data in ways that made poor results seem acceptable. Some trials were designed in ways that made failure more likely, then shelved when they failed as expected.
The evidence of this pattern emerged through rigorous academic analysis. Researchers compared what appeared in published medical journals against the complete trial records held by the FDA. The discrepancy was stark and systematic. When all trials were counted—published and unpublished—antidepressants showed genuine efficacy rates far below the 94% figure doctors believed. The apparent effectiveness was largely an artifact of selective reporting.
Get the 5 biggest receipts every week, straight to your inbox — plus an exclusive PDF: The Top 10 Conspiracy Theories Proven True in 2025-2026. No spam. No agenda. Just the papers they couldn't hide.
You just read "Pharmaceutical companies suppressed negative antidepressant …". We send ones like this every week.
No one's said anything yet. Be the first to drop your take.
This wasn't the unfounded speculation of critics or conspiracy theorists. It was documented fact, established through peer-reviewed research that compared public data against official regulatory records. The studies showed exactly how the publication bias worked and quantified its impact on medical understanding.
Pharmaceutical companies defended themselves by pointing to legal practices. Nothing they did technically violated FDA regulations. Companies were permitted to decide what research to publish. No law required them to broadcast negative trial results. The system itself enabled this behavior.
Yet the consequences were real. Doctors prescribed these medications with confidence in their efficacy that wasn't justified. Patients chose treatments based on inflated effectiveness claims. Insurance companies made coverage decisions informed by misleading statistics. The entire medical establishment operated on systematically distorted information.
This case reveals something deeper than corporate malfeasance. It exposes how institutional structures can perpetuate misinformation even within tightly regulated industries. The FDA knew. Regulators possessed the complete data. Yet the gap between official knowledge and public understanding persisted for years because information moved only one direction—from companies to doctors to patients, with negative findings filtered out at the source.
When we trust institutions with our health, we assume they're working from the same facts we would use to make decisions. This case demonstrates how vulnerable that assumption is. The system was designed to be transparent to regulators but opaque to everyone else. For patients trying to make informed choices, that asymmetry mattered enormously.
Beat the odds
This had a 1.5% chance of leaking — someone talked anyway.
Conspirators
~200Network
Secret kept
18.3 years
Time to 95% exposure
500+ years
